4//SEC Filing
Babiss Lee 4
Accession 0001498376-11-000002
CIK 0001003124other
Filed
Dec 5, 7:00 PM ET
Accepted
Dec 6, 8:31 AM ET
Size
13.5 KB
Accession
0001498376-11-000002
Insider Transaction Report
Form 4
Babiss Lee
Exec. VP - Global Lab Services
Transactions
- Disposition to Issuer
Restricted Stock Units
2011-12-05−10,000→ 0 total→ Common Stock (10,000 underlying) - Disposition to Issuer
Stock Options (to buy)
2011-12-05−30,000→ 0 totalExercise: $27.27→ Common Stock (30,000 underlying) - Disposition to Issuer
Stock Options (to buy)
2011-12-05−15,000→ 0 totalExercise: $26.64→ Common Stock (15,000 underlying) - Disposition to Issuer
Stock Options (to buy)
2011-12-05−46,578→ 0 totalExercise: $20.45→ Common Stock (46,578 underlying)
Footnotes (4)
- [F1]The stock options were cancelled pursuant to the Agreement and Plan of Merger (the "Agreement") by and among Pharmaceutical Prodcut Development, Inc., Jaguar Holdings, LLC and Jaguar Merger Sub, Inc. dated as of October 2, 2011, on the effective date of the merger contemplated by the Agreement (the "Merger") in exchange for a cash payment equal to the difference (if any ) between the exercise price of the stock options and $33.25 multiplied by the number of shares subject to such stock options less any applicable withholding taxes. The options were scheduled to vest in three equal increments on 2/23/12, 2/23/13 and 2/23/14 but vesting was accelerated due to the Merger.
- [F2]These stock options were cancelled pursuant to the Merger in exchange for a cash payment equal to the difference if any between the exercise price of the stock options and $33.25 mulitplied by the number of shares subject to such stock options less any applicable withholding taxes. The options were scheduled to vest in three equal increments on 6/17/11, 6/17/12 and 6/17/13 but vesting was accelerated due to the Merger.
- [F3]These stock options were cancelled pursuant to the Merger in exchange for a cash payment equal to the difference if any between the exercise price of the stock options and $33.25 mulitplied by the number of shares subject to such stock options less any applicable withholding taxes. The options were scheduled to vest in three equal increments on 2/25/11, 2/25/12 and 2/25/13 but vesting was accelerated due to the Merger.
- [F4]Each restricted stock unit (RSU) represents a contingent right to receive one share of PPDI common stock. The RSUs were scheduled to vest in three equal increments on 2/23/12, 2/23/13 and 2/23/14 but became fully vested pursuant to the terms of the Agreement. The RSUs were disposed of pursuant to the terms of the Agreement in exchange for a cash payment of $33.25 per share upon the effective date of the Merger.
Documents
Issuer
PHARMACEUTICAL PRODUCT DEVELOPMENT INC
CIK 0001003124
Entity typeother
Related Parties
1- filerCIK 0001498376
Filing Metadata
- Form type
- 4
- Filed
- Dec 5, 7:00 PM ET
- Accepted
- Dec 6, 8:31 AM ET
- Size
- 13.5 KB